Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review.
Identifieur interne : 000900 ( Main/Exploration ); précédent : 000899; suivant : 000901Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review.
Auteurs : Yogesh Acharya [Irlande (pays)] ; Abida SayedSource :
- Therapeutic advances in infectious disease [ 2049-9361 ]
Abstract
The predicament arising from the coronavirus disease 2019 (COVID-19) pandemic has become one of the most significant modern public health challenges. Despite uncertainties in the viral determinants and pathogenesis, it is crucial to accurately inspect all available evidence to construct accurate clinical guidelines for optimised patient care. This study aims to discuss the available evidence for the use of chloroquine (CQ) and hydroxychloroquine (HCQ) against COVID-19. Early in vitro studies of CQ/HCQ against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are convincing. But contradictory evidence exists on the clinical use of CQ/HCQ, either alone or in combination with azithromycin. As of now, there is no compelling clinical evidence on CQ, HCQ, and azithromycin in COVID-19 and the available evidence is limited to methodologically inferior non-randomised studies. Studies have also shown detrimental drug reactions to CQ and 'HCQ plus azithromycin', mainly cardiac side effects in hospitalised patients with coexisting cardiovascular comorbidities. Therefore, we recommend that physicians avoid high doses and exercise extreme caution in the compassionate use of CQ/HCQ, either alone or in combination with other antiviral drugs.
DOI: 10.1177/2049936120947517
PubMed: 32821381
PubMed Central: PMC7404096
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review.</title><author><name sortKey="Acharya, Yogesh" sort="Acharya, Yogesh" uniqKey="Acharya Y" first="Yogesh" last="Acharya">Yogesh Acharya</name><affiliation wicri:level="1"><nlm:affiliation>Vascular and Endovascular Department, Western Vascular Institute, National University of Ireland, Galway, H91 TK33, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Vascular and Endovascular Department, Western Vascular Institute, National University of Ireland, Galway, H91 TK33</wicri:regionArea><wicri:noRegion>H91 TK33</wicri:noRegion></affiliation></author><author><name sortKey="Sayed, Abida" sort="Sayed, Abida" uniqKey="Sayed A" first="Abida" last="Sayed">Abida Sayed</name><affiliation><nlm:affiliation>Medicine Department, Avalon University School of Medicine, Willemstad, Curacao, Netherlands Antilles.</nlm:affiliation><wicri:noCountry code="subField">Netherlands Antilles</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020 Jan-Dec</date><idno type="RBID">pubmed:32821381</idno><idno type="pmid">32821381</idno><idno type="doi">10.1177/2049936120947517</idno><idno type="pmc">PMC7404096</idno><idno type="wicri:Area/Main/Corpus">000E47</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000E47</idno><idno type="wicri:Area/Main/Curation">000E47</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000E47</idno><idno type="wicri:Area/Main/Exploration">000E47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review.</title><author><name sortKey="Acharya, Yogesh" sort="Acharya, Yogesh" uniqKey="Acharya Y" first="Yogesh" last="Acharya">Yogesh Acharya</name><affiliation wicri:level="1"><nlm:affiliation>Vascular and Endovascular Department, Western Vascular Institute, National University of Ireland, Galway, H91 TK33, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Vascular and Endovascular Department, Western Vascular Institute, National University of Ireland, Galway, H91 TK33</wicri:regionArea><wicri:noRegion>H91 TK33</wicri:noRegion></affiliation></author><author><name sortKey="Sayed, Abida" sort="Sayed, Abida" uniqKey="Sayed A" first="Abida" last="Sayed">Abida Sayed</name><affiliation><nlm:affiliation>Medicine Department, Avalon University School of Medicine, Willemstad, Curacao, Netherlands Antilles.</nlm:affiliation><wicri:noCountry code="subField">Netherlands Antilles</wicri:noCountry></affiliation></author></analytic><series><title level="j">Therapeutic advances in infectious disease</title><idno type="ISSN">2049-9361</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The predicament arising from the coronavirus disease 2019 (COVID-19) pandemic has become one of the most significant modern public health challenges. Despite uncertainties in the viral determinants and pathogenesis, it is crucial to accurately inspect all available evidence to construct accurate clinical guidelines for optimised patient care. This study aims to discuss the available evidence for the use of chloroquine (CQ) and hydroxychloroquine (HCQ) against COVID-19. Early <i>in vitro</i> studies of CQ/HCQ against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are convincing. But contradictory evidence exists on the clinical use of CQ/HCQ, either alone or in combination with azithromycin. As of now, there is no compelling clinical evidence on CQ, HCQ, and azithromycin in COVID-19 and the available evidence is limited to methodologically inferior non-randomised studies. Studies have also shown detrimental drug reactions to CQ and 'HCQ plus azithromycin', mainly cardiac side effects in hospitalised patients with coexisting cardiovascular comorbidities. Therefore, we recommend that physicians avoid high doses and exercise extreme caution in the compassionate use of CQ/HCQ, either alone or in combination with other antiviral drugs.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32821381</PMID><DateRevised><Year>2020</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2049-9361</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><PubDate><MedlineDate>2020 Jan-Dec</MedlineDate></PubDate></JournalIssue><Title>Therapeutic advances in infectious disease</Title><ISOAbbreviation>Ther Adv Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review.</ArticleTitle><Pagination><MedlinePgn>2049936120947517</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/2049936120947517</ELocationID><Abstract><AbstractText>The predicament arising from the coronavirus disease 2019 (COVID-19) pandemic has become one of the most significant modern public health challenges. Despite uncertainties in the viral determinants and pathogenesis, it is crucial to accurately inspect all available evidence to construct accurate clinical guidelines for optimised patient care. This study aims to discuss the available evidence for the use of chloroquine (CQ) and hydroxychloroquine (HCQ) against COVID-19. Early <i>in vitro</i> studies of CQ/HCQ against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are convincing. But contradictory evidence exists on the clinical use of CQ/HCQ, either alone or in combination with azithromycin. As of now, there is no compelling clinical evidence on CQ, HCQ, and azithromycin in COVID-19 and the available evidence is limited to methodologically inferior non-randomised studies. Studies have also shown detrimental drug reactions to CQ and 'HCQ plus azithromycin', mainly cardiac side effects in hospitalised patients with coexisting cardiovascular comorbidities. Therefore, we recommend that physicians avoid high doses and exercise extreme caution in the compassionate use of CQ/HCQ, either alone or in combination with other antiviral drugs.</AbstractText><CopyrightInformation>© The Author(s), 2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Acharya</LastName><ForeName>Yogesh</ForeName><Initials>Y</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1829-5911</Identifier><AffiliationInfo><Affiliation>Vascular and Endovascular Department, Western Vascular Institute, National University of Ireland, Galway, H91 TK33, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayed</LastName><ForeName>Abida</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medicine Department, Avalon University School of Medicine, Willemstad, Curacao, Netherlands Antilles.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Infect Dis</MedlineTA><NlmUniqueID>101606715</NlmUniqueID><ISSNLinking>2049-9361</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">chloroquine</Keyword><Keyword MajorTopicYN="N">evidence</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">review</Keyword></KeywordList><CoiStatement>Conflict of interest statement: The authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32821381</ArticleId><ArticleId IdType="doi">10.1177/2049936120947517</ArticleId><ArticleId IdType="pii">10.1177_2049936120947517</ArticleId><ArticleId IdType="pmc">PMC7404096</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Med (N Y). 2020 Jun 5;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32838355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670</Citation><ArticleIdList><ArticleId IdType="pubmed">32196083</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation><ArticleIdList><ArticleId IdType="pubmed">32492293</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1974 Sep 15;14(3):379-85</Citation><ArticleIdList><ArticleId IdType="pubmed">4459273</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19506054</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 1961 May;6:143-52</Citation><ArticleIdList><ArticleId IdType="pubmed">13747452</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Hum Retroviruses. 1999 Sep 20;15(14):1241-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10505672</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2020 May 8;24(1):210</Citation><ArticleIdList><ArticleId IdType="pubmed">32384908</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation><ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Feb 20;382(8):727-733</Citation><ArticleIdList><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Acad Emerg Med. 2020 Jun;27(6):493-504</Citation><ArticleIdList><ArticleId IdType="pubmed">32359203</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2020 May;121:A5-A7</Citation><ArticleIdList><ArticleId IdType="pubmed">32336471</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Jul;92(7):776-785</Citation><ArticleIdList><ArticleId IdType="pubmed">32297988</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation><ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Soc Exp Biol Med. 1973 Mar;142(3):1018-22</Citation><ArticleIdList><ArticleId IdType="pubmed">4348088</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1966 Mar;28(3):355-62</Citation><ArticleIdList><ArticleId IdType="pubmed">18611466</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 May 19;323(19):1897-1898</Citation><ArticleIdList><ArticleId IdType="pubmed">32208486</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662</Citation><ArticleIdList><ArticleId IdType="pubmed">32347743</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 May;92(5):491-494</Citation><ArticleIdList><ArticleId IdType="pubmed">32056249</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Nov 12;11(1):5749</Citation><ArticleIdList><ArticleId IdType="pubmed">33184277</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Jun 23;323(24):2493-2502</Citation><ArticleIdList><ArticleId IdType="pubmed">32392282</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Clin Cancer Res. 2020 May 12;39(1):86</Citation><ArticleIdList><ArticleId IdType="pubmed">32398164</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2016 Oct 12;355:i4919</Citation><ArticleIdList><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab Syndr. 2020 Jul - Aug;14(4):589-596</Citation><ArticleIdList><ArticleId IdType="pubmed">32417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation><ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart Rhythm. 2020 Sep;17(9):1417-1422</Citation><ArticleIdList><ArticleId IdType="pubmed">32387247</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Hum Retroviruses. 1990 Apr;6(4):481-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1692728</ArticleId></ArticleIdList></Reference><Reference><Citation>J Travel Med. 2020 Mar 13;27(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">32052846</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Hum Retroviruses. 1993 Jan;9(1):91-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8427717</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2411-2418</Citation><ArticleIdList><ArticleId IdType="pubmed">32379955</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Rheum Dis. 2020 May;23(5):613-619</Citation><ArticleIdList><ArticleId IdType="pubmed">32281213</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 May 12;323(18):1824-1836</Citation><ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>Neth Heart J. 2020 Jul;28(7-8):406-409</Citation><ArticleIdList><ArticleId IdType="pubmed">32350818</ArticleId></ArticleIdList></Reference><Reference><Citation>J Crit Care. 2020 Jun;57:279-283</Citation><ArticleIdList><ArticleId IdType="pubmed">32173110</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2020 Jul;123:120-126</Citation><ArticleIdList><ArticleId IdType="pubmed">32330521</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Cardiol. 2020 Sep 1;5(9):1036-1041</Citation><ArticleIdList><ArticleId IdType="pubmed">32936252</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2020 Sep;39(9):1629-1635</Citation><ArticleIdList><ArticleId IdType="pubmed">32333222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Emerg Med. 1990 Jan;19(1):47-50</Citation><ArticleIdList><ArticleId IdType="pubmed">2297155</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gesamte Virusforsch. 1972;36(1):93-104</Citation><ArticleIdList><ArticleId IdType="pubmed">4335025</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Soc Exp Biol Med. 1971 Apr;136(4):1289-93</Citation><ArticleIdList><ArticleId IdType="pubmed">4324360</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2008 May;65(5):674-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18279478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2006 Feb;6(2):67-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16439323</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 1996 Nov-Dec;18(6):1080-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9001825</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1952 Nov;96(5):451-63</Citation><ArticleIdList><ArticleId IdType="pubmed">13000056</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Irlande (pays)</li></country></list><tree><noCountry><name sortKey="Sayed, Abida" sort="Sayed, Abida" uniqKey="Sayed A" first="Abida" last="Sayed">Abida Sayed</name></noCountry><country name="Irlande (pays)"><noRegion><name sortKey="Acharya, Yogesh" sort="Acharya, Yogesh" uniqKey="Acharya Y" first="Yogesh" last="Acharya">Yogesh Acharya</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000900 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000900 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32821381
|texte= Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32821381" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |